Post-translational modifications of protein biopharmaceuticals.

  title={Post-translational modifications of protein biopharmaceuticals.},
  author={Gary Walsh},
  journal={Drug discovery today},
  volume={15 17-18},
  • G. Walsh
  • Published 15 April 2009
  • Biology
  • Drug discovery today

Figures and Tables from this paper

Genetic engineering approaches to improve posttranslational modification of biopharmaceuticals in different production platforms

The number of approved biopharmaceuticals, where product quality attributes remain of major importance, is increasing steadily and it is now possible to address general as well as host‐ or biophARMaceutical‐specific product quality obstacles.

Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications

This paper has classified these modifications into multiple categories, according to their processing locations and enzymatic involvement during the trafficking events, for improving functional characteristics and attributes of protein-based biopharmaceutical products.

Post-translational modification of plant-made foreign proteins; glycosylation and beyond.

Protein deamidation in biopharmaceutical manufacture: understanding, control and impact

The impact of deamidated forms of biopharmaceuticals should be thoroughly studied, as they may not necessarily represent deleterious changes to the function of the molecule or the quality of the final product.

Prospects in the Total Synthesis of Protein Therapeutics

  • J. Chalker
  • Biology, Chemistry
    Chemical biology & drug design
  • 2013
This review highlights the emerging techniques for the total synthesis of proteins, with a special focus on the possibility of accessing therapeutic targets through chemoselective peptide ligations.

Physicochemical Characterization, Glycosylation Pattern and Biosimilarity Assessment of the Fusion Protein Etanercept

Etanercept is a soluble fusion protein of the tumor necrosis factor receptor (TNFR) extracellular domain, linked to an Fc part of IgG1. It possesses three N- and 13 O-glycosylation sites. Due to its

Characterization of Biopharmaceuticals Focusing on Antibody Therapeutics

This chapter introduces several analytical techniques for assessing characteristics of biopharmaceuticals focusing on monoclonal antibodies (mAbs) using mass spectrometry and multi-attribute method approach.

Contemporary Enzyme-Based Methods for Recombinant Proteins In Vitro Phosphorylation

In this review, the current enzyme-based possibilities for in vitro phosphorylation of peptides and recombinant proteins and the added value that immobilized kinases provide are outlined.

Host cell protein analysis in therapeutic protein bioprocessing – methods and applications

Different methods for the comparison of bioprocessing strategies during scale‐up and purification development are compared and include immunospecific methods, such as ELISA, western blot, and threshold, and non‐specific methods,such as 2D‐DIGE and2D‐HPLC combined with MS.



Post-translational modifications in the context of therapeutic proteins

A better understanding of the relationship between structure and function is understood for many PTMs but remains incomplete for others, particularly in the case of complex PTMs, such as glycosylation.

Glycome profiling using modern glycomics technology: technical aspects and applications

This review highlights the evolution of glycan profiling tools in the past 5 years and focuses on capillary electrophoresis, liquid chromatography, mass spectrometry and lectin microarrays.

Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins.

The discovery of darbepoetin alfa (DA), a hyperglycosylated analogue of erythropoietin that contains two additional N-linked carbohydrates, a threefold increase in serum half-life and increased in vivo activity compared to recombinant human ery Anthropo-EPO, is discussed.

Production and glycosylation of plant-made pharmaceuticals: the antibodies as a challenge.

Transgenic plants are focused on as a promising system for the scale-up and processing of plant-made pharmaceuticals and the advantages and limitations induced by glycosylation of plants-made antibodies for human therapy are pointed out.

Post-translational Modifications Required for Coagulation Factor Secretion and Function

The role of post-translational modification in protein function investigators have studied proteins treated with chemicals or enzymes to remove modifications, proteins synthesized in the presence of inhibitors of specific modification reactions, proteins expressed in either different cell types or in cell mutants with defects in specific enzymatic machinery required to perform modifications, or proteins engineered through recombinant DNA technology that contain mutations that prevent modifications.

The production of biopharmaceuticals in plant systems.

Glycosylation as a strategy to improve antibody-based therapeutics

Current knowledge of methods and avenues for their exploitation in the clinic are summarized, which allow the production of rMAbs bearing pre-selected oligosaccharides — glycoforms — to provide maximum efficacy for a given disease indication.

Post‐translational modifications in proteins involved in blood coagulation

The post-translational modifications that occur in blood coagulation proteins are described and, where known, their functional implications are described.